SCHEMBL3527965

SCHEMBL3527965

NC(=O)c1ncc2c(n1)CCC(NC(=O)Cc1cccc3ccccc13)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.45
CDK5 Q00535 3/20 0.41
CDK5R1 Q15078 3/20 0.41
MAPK8 P45983 2/20 0.41
GSK3B P49841 1/20 0.41
ALDH1A1 P00352 2/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
MTNR1A P48039 3/20 0.39
MTNR1B P49286 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HDAC3 O15379 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC4 P56524 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527966 0.88 SIGMAR1 (0.47) SIGMAR1CDK5CDK5R1GSK3BALDH1A1
SCHEMBL3535953 0.80 MAPK8 (0.37) MAPK8MTNR1AMTNR1BMEN1LMNA
SCHEMBL3532112 0.78 EPHX1 (0.51) MTNR1AMTNR1BHDAC1LMNA
SCHEMBL3534050 0.77 HPGD (0.42) MTNR1AMTNR1BSMN1; SMN2MEN1HPGD
SCHEMBL3530608 0.77 EPHX2 (0.50) SIGMAR1CDK5CDK5R1MAPK8ALDH1A1
SCHEMBL3530714 0.75 L3MBTL1 (0.39) ALDH1A1MTNR1AMTNR1BHDAC3HDAC1
SCHEMBL3529689 0.74 HDAC8 (0.46) SIGMAR1ALDH1A1SMN1; SMN2HDAC8KDM4E
SCHEMBL6846989 0.73 SIGMAR1 (0.48) SIGMAR1CDK5CDK5R1MAPK8GSK3B
SCHEMBL2751955 0.73 SIGMAR1 (0.70) SIGMAR1ALDH1A1CCNA2CDK2CCNA1
SCHEMBL3532001 0.72 HCRTR1 (0.43) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742925-B1 SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS GRUENENTHAL GMBH (DE) 2014-04-23 EP claimed
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2007-10-25 US claimed
US-7662828-B2 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2010-02-16 US disclosed
US-20090176811-A1 Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds GRUENENTHAL GMBH (DE) 2009-07-09 US disclosed
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds P2RX7, CYP2C8, P2RX5 SIGMAR1 1035/4885CDK5 297/4885CDK5R1 727/4885
US-20090176811-A1 Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds P2RX7, P2RX5, DPYD SIGMAR1 1206/4885CDK5 266/4885CDK5R1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.